Diagenode

CRISPR/Cas9 C-terminal Antibody (sample size)

Catalog Number
Format
Price
C15200231-10
10 µg
$130.00
  Bulk order
Other format



Monoclonal antibody raised in mouse against the C-terminus of Cas9 nuclease (CRISPR-associated protein 9).

Lot001
Concentration2.2 μg/μl
Species reactivityStreptococcus pyogenes
TypeMonoclonal
PurityProtein G purified
HostMouse
Storage ConditionsStore at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
ChIP * 5 μg/ChIP Fig 1
Western Blotting 1:6,000 Fig 2
Immunofluorescence 1:100 Fig 3

* Please note that the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-10 μg per IP.

  • Validation Data

    CRISPR/Cas9 C-terminal Antibody ChIP Grade

    Figure 1. ChIP using the Diagenode monoclonal antibody directed against Cas9
    ChIP was performed on NIH3T3 cells stably expressing GFP-H2B, nuclease dead Cas9, and a GFP-targeting gRNA. 50 μg chromatin was incubated overnight at 4°C with 5 μg of either the Diagenode antibody against Cas9 (cat. No. C15200231) or the anti-blue antibody (C15200213), used as a negative IP control. qPCR was performed with primers speci c for the GFP gene, and for a non-targeted region (protein kinase C delta, Prkcd), used as negative control. Figure 1 shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis).

    CRISPR/Cas9 C-terminal Antibody validated in Western Blot

    Figure 2. Western blot analysis using the Diagenode monoclonal antibody directed against CRISPR/Cas9
    Western blot was performed on protein extracts from HeLa cells transfected with Cas9 (lane 2) or on untransfected control cells (lane 1) using the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200231). The antibody was diluted 1:6,000 in TBS-T containing 3% NFDM. The marker is shown on the left, position of the Cas9 protein is indicated on the right.

    CRISPR/Cas9 C-terminal Antibody validated in  Immunofluorescence

    Figure 3. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9
    HeLa cells expressing Cas9 under the control of the tight TRE promoter and untransfected control cells were fixed in methanol at -20°C, permeabilized with acetone at -20°C and blocked with PBS containing 2% BSA. The cells were stained with the Cas9 C-terminal antibody (Cat. No. C15200231) diluted 1:100, followed by incubation with a donkey anti-mouse secondary antibody coupled to AF488 (upper panel). Nuclei were counter-stained with Hoechst 33342 (lower panel).

  • Target Description

    CRISPR systems are adaptable immune mechanisms which are present in many bacteria to protect themselves from foreign nucleic acids, such as viruses, transposable elements or plasmids. Recently, the CRISPR/Cas9 (CRISPR-associated protein 9 nuclease, UniProtKB/Swiss-Prot entry Q99ZW2) system from S. pyogenes has been adapted for inducing sequence-specific double stranded breaks and targeted genome editing. This system is unique and flexible due to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence and can be used to induce indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate upregulation of specific endogenous genes or to alter histone modifications or DNA methylation.

  •  Applications
    ChIP-qPCR (ab)
    Read more
    WB
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    IF
    Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more
  •  Documents
    Datasheet CRISPR/Cas9 C-terminal monoclonal antibody C15200231 DATASHEET
    Datasheet of the CRISPR/Cas9 C-terminal monoclonal antibody raised in mouse against the C-te...
    Download
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Download
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
    Download
  •  Safety sheets
    CRISPR/Cas9 C-terminal antibody SDS US en Download
    CRISPR/Cas9 C-terminal antibody SDS GB en Download
    CRISPR/Cas9 C-terminal antibody SDS BE fr Download
    CRISPR/Cas9 C-terminal antibody SDS FR fr Download
    CRISPR/Cas9 C-terminal antibody SDS ES es Download
    CRISPR/Cas9 C-terminal antibody SDS DE de Download
    CRISPR/Cas9 C-terminal antibody SDS JP ja Download
    CRISPR/Cas9 C-terminal antibody SDS BE nl Download
  •  Publications

    How to properly cite this product in your work

    Diagenode strongly recommends using this: CRISPR/Cas9 C-terminal Antibody (sample size) (Diagenode Cat# C15200231-10 Lot# 001). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    A self-inactivating system for AAV-mediated in vivo base editing
    Zuo Y. et al.
    DNA base editors have been harnessed as an exciting therapeutic platform for human diseases and are rapidly progressing into human clinical trials. However, persistent expression of base editors delivered via adeno-associated virus (AAV) poses concerns with specificity and immunogenicity. Here we develop selfinactiv...

Events

  • AACR 2024
    San Diego, California, USA
    Apr 5-Apr 10, 2024
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics